The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
Open accessAbstract
Please cite this paper as: McKimm‐Breschkin (2012) Influenza neuraminidase inhibitors: Antiviral action and mechanisms of resistance. Influenza and Other Respiratory Viruses 7(Suppl. 1), 25–36. There are two major classes of antivirals available for the treatment and prevention of influenza, the M2 inhibitors and the neuraminidase inhibitors (NAIs). The M2 inhibitors are cheap, but they are only effective against influenza A viruses, and resistance arises rapidly. The current influenza A H3N2 and pandemic A(H1N1)pdm09 viruses are already resistant to the M2 inhibitors as are many H5N1 viruses. There are four NAIs licensed in some parts of the world, zanamivir, oseltamivir, peramivir, and a long‐acting NAI, laninamivir. This review focuses on resistance to the NAIs. Because of differences in their chemistry and subtle differences in NA structures, resistance can be both NAI‐ and subtype specific. This results in different drug resistance profiles, for example, the H274Y mutation confers resistance to oseltamivir and peramivir, but not to zanamivir, and only in N1 NAs. Mutations at E119, D198, I222, R292, and N294 can also reduce NAI sensitivity. In the winter of 2007–2008, an oseltamivir‐resistant seasonal influenza A(H1N1) strain with an H274Y mutation emerged in the northern hemisphere and spread rapidly around the world. In contrast to earlier evidence of such resistant viruses being unfit, this mutant virus remained fully transmissible and pathogenic and became the major seasonal A(H1N1) virus globally within a year. This resistant A(H1N1) virus was displaced by the sensitive A(H1N1)pdm09 virus. Approximately 0·5–1·0% of community A(H1N1)pdm09 isolates are currently resistant to oseltamivir. It is now apparent that variation in non‐active site amino acids can affect the fitness of the enzyme and compensate for mutations that confer high‐level oseltamivir resistance resulting in minimal impact on enzyme function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862
Kim, C. U., Lew, W., Williams, M. A., Liu, H., Zhang, L., Swaminathan, S., Bischofberger, N., Chen, M. S., Mendel, D. B., Tai, C. Y., et al. (1997) · Journal of the American Chemical Society · doi:10.1021/ja963036t · Cited by 1,100
Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection
de Jong, M. D., Thanh, T. T., Khanh, T. H., Hien, V. M., Smith, G. J. D., Chau, N. V., Cam, B. V., Qui, P. T., Ha, D. Q., Guan, Y., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa054512 · Cited by 901
Antiviral Activity of 1-Adamantanamine (Amantadine)
Davies, W. L., Grunert, R. R., Haff, R. F., McGahen, J. W., Neumayer, E. M., Paulshock, M., Watts, J. C., Wood, T. R., Hermann, E. C., & Hoffmann, C. E. (1964) · Science · doi:10.1126/science.144.3620.862 · Cited by 838
Potier, M., Mameli, L., Bélisle, M., Dallaire, L., & Melançon, S. B. (1979) · Analytical Biochemistry · doi:10.1016/0003-2697(79)90362-2 · Cited by 815
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design
Russell, R. J., Haire, L. F., Stevens, D. J., Collins, P. J., Lin, Y. P., Blackburn, G. M., Hay, A. J., Gamblin, S. J., & Skehel, J. J. (2006) · Nature · doi:10.1038/nature05114 · Cited by 813
Resistant influenza A viruses in children treated with oseltamivir: descriptive study
Kiso, M., Mitamura, K., Sakai-Tagawa, Y., Shiraishi, K., Kawakami, C., Kimura, K., Hayden, F. G., Sugaya, N., & Kawaoka, Y. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16934-1 · Cited by 786
Oral oseltamivir treatment of influenza in children
WHITLEY, R. J., HAYDEN, F. G., REISINGER, K. S., YOUNG, N., DUTKOWSKI, R., IPE, D., MILLS, R. G., & WARD, P. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200102000-00002 · Cited by 711
Isolation of drug-resistant H5N1 virus
Le, Q. M., Kiso, M., Someya, K., Sakai, Y. T., Nguyen, T. H., Nguyen, K. H. L., Pham, N. D., Ngyen, H. H., Yamada, S., Muramoto, Y., et al. (2005) · Nature · doi:10.1038/4371108a · Cited by 693
Bright, R. A. (2006) · JAMA · doi:10.1001/jama.295.8.joc60020 · Cited by 671
Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance
Bloom, J. D., Gong, L. I., & Baltimore, D. (2010) · Science · doi:10.1126/science.1187816 · Cited by 649
Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants
Collins, P. J., Haire, L. F., Lin, Y. P., Liu, J., Russell, R. J., Walker, P. A., Skehel, J. J., Martin, S. R., Hay, A. J., & Gamblin, S. J. (2008) · Nature · doi:10.1038/nature06956 · Cited by 534
Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States
Dharan, N. J. (2009) · JAMA · doi:10.1001/jama.2009.294 · Cited by 527
Sheu, T. G., Deyde, V. M., Okomo-Adhiambo, M., Garten, R. J., Xu, X., Bright, R. A., Butler, E. N., Wallis, T. R., Klimov, A. I., & Gubareva, L. V. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00555-08 · Cited by 480
Evidence for Zanamivir Resistance in an Immunocompromised Child Infected with Influenza B Virus
Gubareva, L. V., Matrosovich, M. N., Brenner, M. K., Bethell, R. C., & Webster, R. G. (1998) · The Journal of Infectious Diseases · doi:10.1086/314440 · Cited by 432
Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic
Ward, P., Small, I., Smith, J., Suter, P., & Dutkowski, R. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki018 · Cited by 428
Varghese, J. N., McKimm‐Breschkin, J. L., Caldwell, J. B., Kortt, A. A., & Colman, P. M. (1992) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340140302 · Cited by 402
Self-citationBabu, Y. S., Chand, P., Bantia, S., Kotian, P., Dehghani, A., El-Kattan, Y., Lin, T.-H., Hutchison, T. L., Elliott, A. J., Parker, C. D., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0002679 · Cited by 384
Monto, A. S., McKimm-Breschkin, J. L., Macken, C., Hampson, A. W., Hay, A., Klimov, A., Tashiro, M., Webster, R. G., Aymard, M., Hayden, F. G., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01339-05 · Cited by 364
Self-citationOseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season
Meijer, A., Lackenby, A., Hungnes, O., Lina, B., van der Werf, S., Schweiger, B., Opp, M., Paget, J., van de Kassteele, J., Hay, A. J., et al. (2009) · Emerging infectious diseases · doi:10.3201/eid1504.081280 · Cited by 362
Selection of Influenza Virus Mutants in Experimentally Infected Volunteers Treated with Oseltamivir
Gubareva, L. V., Kaiser, L., Matrosovich, M. N., Soo‐Hoo, Y., & Hayden, F. G. (2001) · The Journal of Infectious Diseases · doi:10.1086/318537 · Cited by 318
Influenza Viruses Resistant to the Antiviral Drug Oseltamivir: Transmission Studies in Ferrets
Herlocher, M. L., Truscon, R., Elias, S., Yen, H., Roberts, N. A., Ohmit, S. E., & Monto, A. S. (2004) · The Journal of Infectious Diseases · doi:10.1086/424572 · Cited by 292
McKimm-Breschkin, J., Trivedi, T., Hampson, A., Hay, A., Klimov, A., Tashiro, M., Hayden, F., & Zambon, M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2264-2272.2003 · Cited by 291
Self-citationHurt, A. C., Ernest, J., Deng, Y.-M., Iannello, P., Besselaar, T. G., Birch, C., Buchy, P., Chittaganpitch, M., Chiu, S.-C., Dwyer, D., et al. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.03.003 · Cited by 277
Recovery of Drug‐Resistant Influenza Virus from Immunocompromised Patients: A Case Series
Ison, M. G., Gubareva, L. V., Atmar, R. L., Treanor, J., & Hayden, F. G. (2006) · The Journal of Infectious Diseases · doi:10.1086/500465 · Cited by 261
Distribution of Amantadine‐Resistant H5N1 Avian Influenza Variants in Asia
Cheung, C., Rayner, J. M., Smith, G. J. D., Wang, P., Naipospos, T. S. P., Zhang, J., Yuen, K., Webster, R. G., Peiris, J. S. M., Guan, Y., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/504723 · Cited by 260
Hurt, A. C., Selleck, P., Komadina, N., Shaw, R., Brown, L., & Barr, I. G. (2007) · Antiviral Research · doi:10.1016/j.antiviral.2006.10.004 · Cited by 230
Cass, L. M. R., Efthymiopoulos, C., & Bye, A. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936001-00001 · Cited by 227
Emergence of Oseltamivir-Resistant Pandemic H1N1 Virus during Prophylaxis
Baz, M., Abed, Y., Papenburg, J., Bouhy, X., Hamelin, M.-È., & Boivin, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0910060 · Cited by 227
Emergence of Influenza B Viruses With Reduced Sensitivity to Neuraminidase Inhibitors
Hatakeyama, S., Sugaya, N., Ito, M., Yamazaki, M., Ichikawa, M., Kimura, K., Kiso, M., Shimizu, H., Kawakami, C., Koike, K., et al. (2007) · JAMA · doi:10.1001/jama.297.13.1435 · Cited by 216
Gubareva, L. V., Robinson, M. J., Bethell, R. C., & Webster, R. G. (1997) · Journal of Virology · doi:10.1128/jvi.71.5.3385-3390.1997 · Cited by 212
Wetherall, N. T., Trivedi, T., Zeller, J., Hodges-Savola, C., McKimm-Breschkin, J. L., Zambon, M., & Hayden, F. G. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.2.742-750.2003 · Cited by 207
Self-citationVarghese, J. N., Smith, P. W., Sollis, S. L., Blick, T. J., Sahasrabudhe, A., McKimm-Breschkin, J. L., & Colman, P. M. (1998) · Structure · doi:10.1016/s0969-2126(98)00075-6 · Cited by 201
Self-citationEmergence of a Multidrug-Resistant Pandemic Influenza A (H1N1) Virus
van der Vries, E., Stelma, F. F., & Boucher, C. A. B. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1003749 · Cited by 187
McKimm-Breschkin, J. L., Sahasrabudhe, A., Blick, T. J., McDonald, M., Colman, P. M., Hart, G. J., Bethell, R. C., & Varghese, J. N. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2456-2462.1998 · Cited by 183
Self-citationBaz, M., Abed, Y., McDonald, J., & Boivin, G. (2006) · Clinical Infectious Diseases · doi:10.1086/508777 · Cited by 179
Stephenson, I., Democratis, J., Lackenby, A., McNally, T., Smith, J., Pareek, M., Ellis, J., Bermingham, A., Nicholson, K., & Zambon, M. (2009) · Clinical Infectious Diseases · doi:10.1086/596311 · Cited by 174
Abed, Y., Baz, M., & Boivin, G. (2006) · Antiviral Therapy · doi:10.1177/135965350601100804 · Cited by 166
Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets
Herlocher, M. L., Carr, J., Ives, J., Elias, S., Truscon, R., Roberts, N. A., & Monto, A. S. (2002) · Antiviral Research · doi:10.1016/s0166-3542(01)00214-5 · Cited by 158
Memoli, M. J., Hagey, R. J., Hassantoufighi, A., Eichelberger, M. C., & Taubenberger, J. K. (2010) · Clinical Infectious Diseases · doi:10.1086/651605 · Cited by 154
Inefficient Transmission of H5N1 Influenza Viruses in a Ferret Contact Model
Yen, H., Lipatov, A. S., Ilyushina, N. A., Govorkova, E. A., Franks, J., Yılmaz, N., Douglas, A., Hay, A. J., Krauss, S. L., Rehg, J. E., et al. (2007) · Journal of Virology · doi:10.1128/jvi.00170-07 · Cited by 150
A Community Cluster of Oseltamivir-Resistant Cases of 2009 H1N1 Influenza
Mai, L. Q., Wertheim, H. F. L., Dương, T. N., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0910448 · Cited by 136
Community Transmission of Oseltamivir-Resistant A(H1N1)pdm09 Influenza
Hurt, A. C., Hardie, K., Wilson, N. J., Deng, Y.-M., Maggi Osbourn, B. N., Gehrig, N., & Kelso, A. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1111078 · Cited by 130
Reduced Sensitivity of Influenza A (H5N1) to Oseltamivir
McKimm‐Breschkin, J. L., Selleck, P., Usman, T. B., & Johnson, M. A. (2007) · Emerging infectious diseases · doi:10.3201/eid1309.07-0164 · Cited by 130
Self-citationTramontana, A. R., George, B., Hurt, A. C., Doyle, J. S., Langan, K., Reid, A. B., Harper, J. M., Thursky, K., Worth, L. J., Dwyer, D. E., et al. (2010) · Emerging Infectious Diseases · doi:10.3201/eid1607.091691 · Cited by 127
Structural basis for oseltamivir resistance of influenza viruses
Collins, P. J., Haire, L. F., Lin, Y., Liu, J., Russell, R. J., Walker, P. A., Martin, S. R., Daniels, R. S., Gregory, V., Skehel, J. J., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.07.017 · Cited by 121
In Vitro Generation of Neuraminidase Inhibitor Resistance in A(H5N1) Influenza Viruses
Hurt, A. C., Holien, J. K., & Barr, I. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00334-09 · Cited by 120
Ilyushina, N. A., Hay, A. J., Yılmaz, N., Boon, A. C. M., Webster, R. G., & Govorkova, E. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01579-07 · Cited by 117
Duan, S., Boltz, D. A., Seiler, P., Li, J., Bragstad, K., Nielsen, L. P., Webby, R. J., Webster, R. G., & Govorkova, E. A. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001022 · Cited by 106
Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus Infections, United States, 2010–11
Storms, A. D., Gubareva, L. V., Su, S., Wheeling, J. T., Okomo‐Adhiambo, M., Pan, C., Reisdorf, E. S., George, K. S., Myers, R. A., Wotton, J. T., et al. (2012) · Emerging infectious diseases · doi:10.3201/eid1802.111466 · Cited by 97
Zürcher, T. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl321 · Cited by 97
Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers
Wattanagoon, Y., Stepniewska, K., Lindegårdh, N., Pukrittayakamee, S., Silachamroon, U., Piyaphanee, W., Singtoroj, T., Hanpithakpong, W., Davies, G., Tärning, J., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00588-08 · Cited by 97
Ilyushina, N. A., Seiler, J. P., Rehg, J. E., Webster, R. G., & Govorkova, E. A. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000933 · Cited by 96
Oseltamivir-Resistant Influenza A Pandemic (H1N1) 2009 Virus, Hong Kong, China
Chen, H., Cheung, C. L., Tai, H., et al. (2009) · Emerging infectious diseases · doi:10.3201/eid1512.091057 · Cited by 93
Structural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B Viruses
Oakley, A. J., Barrett, S., Peat, T. S., Newman, J. M., Streltsov, V. A., Waddington, L. J., Saito, T., Tashiro, M., & McKimm‐Breschkin, J. L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100621s · Cited by 86
Self-citationOo, C., Barrett, J., Hill, G., Mann, J., Dorr, A. E., Dutkowski, R. T., & Ward, P. (2001) · Pediatric Drugs · doi:10.2165/00128072-200103030-00005 · Cited by 76
Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996–2007
Tashiro, M., McKimm‐Breschkin, J. L., Saito, T., Klimov, A. I., Macken, C. A., Zambon, M. C. F. A., Hayden, F. G., & for the Neuraminidase Inhibitor Susceptibility Network (2008) · Antiviral Therapy · doi:10.3851/imp1194 · Cited by 72
Self-citationCoexistence of two adamantane binding sites in the influenza A M2 ion channel
Rosenberg, M., & Casarotto, M. G. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002051107 · Cited by 69
Management of Influenza: Use of New Antivirals and Resistance in Perspective
Jackson, H. C., Roberts, N. A., Wang, Z. M., & Belshe, R. B. (2000) · Clinical Drug Investigation · doi:10.2165/00044011-200020060-00007 · Cited by 68
Morrison, D., Roy, S. K., Rayner, C. R., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001305 · Cited by 63
Peng, A., Milleri, S., & Stein, D. S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.7.1974-1976.2000 · Cited by 60
Harvala, H., Gunson, R. N., Simmonds, P., et al. (2010) · Eurosurveillance · doi:10.2807/ese.15.14.19536-en · Cited by 54
Evolution of drug resistance in multiple distinct lineages of H5N1 avian influenza
Hill, A. W., Guralnick, R., Wilson, M. J. C., Habib, F., & Janies, D. A. (2008) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2008.10.006 · Cited by 53
Rare Influenza A (H3N2) Variants with Reduced Sensitivity to Antiviral Drugs
Dapat, C., Suzuki, Y. A., Saito, R., et al. (2010) · Emerging infectious diseases · doi:10.3201/eid1603.091321 · Cited by 47
GS4071 Is a Slow-Binding Inhibitor of Influenza Neuraminidase from Both A and B Strains
Kati, W. M., Saldivar, A. C., Mohamadi, F., Sham, H. L., Laver, W. G., & Kohlbrenner, W. E. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8282 · Cited by 44
A Single Sequence Change Destabilizes the Influenza Virus Neuraminidase Tetramer
Colacino, J. M., Chirgadze, N. Y., Garman, E. F., Murti, K. G., Loncharich, R. J., Baxter, A. J., Staschke, K. A., & Laver, W. G. (1997) · Virology · doi:10.1006/viro.1997.8709 · Cited by 43
Baum, E. Z., Wagaman, P. C., Ly, L., Turchi, I. J., Le, J., Bucher, D. J., & Bush, K. (2003) · Antiviral Research · doi:10.1016/s0166-3542(03)00011-1 · Cited by 42
Emergence of Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus within 48 Hours
Inoue, M., Barkham, T., Leo, Y., Chan, K.-P., Chow, A. L., Wong, C. W., Lee, R. T.-C., Maurer‐Stroh, S., Lin, R. T. P., & Lin, C. (2010) · Emerging infectious diseases · doi:10.3201/eid1610.100688 · Cited by 40
Barrett, S., Mohr, P. G., Schmidt, P. M., & McKimm‐Breschkin, J. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023627 · Cited by 38
Self-citationHart, G. J., & Bethell, R. C. (1995) · PubMed · Cited by 37
Antivirals and Influenza: Frequency of Resistance
Monto, A. S. (2008) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318168b739 · Cited by 24
Substrate, Inhibitor, or Antibody Stabilizes the Glu 119 Gly Mutant Influenza Virus Neuraminidase
Sahasrabudhe, A., Lawrence, L. J., Epa, V. C., Varghese, J. N., Colman, P. M., & McKimm‐Breschkin, J. L. (1998) · Virology · doi:10.1006/viro.1998.9222 · Cited by 16
Self-citationNews About Influenza B Drug Resistance That Cannot Be Ignored
Moscona, A., & McKimm‐Breschkin, J. L. (2007) · JAMA · doi:10.1001/jama.297.13.1492 · Cited by 16
Self-citationIn vitro selection of influenza B viruses with reduced sensitivity to neuraminidase inhibitors
Hatakeyama, S., Ozawa, M., & Kawaoka, Y. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03313.x · Cited by 9
Cited by
Small-Molecule Library Screening by Docking with PyRx
Dallakyan, S., & Olson, A. J. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2269-7_19 · Cited by 3,998
Krammer, F., Smith, G. J. D., Fouchier, R. A. M., Peiris, M., Kedzierska, K., Doherty, P. C., Palese, P., Shaw, M. L., Treanor, J., Webster, R. G., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0002-y · Cited by 1,570
Influenza Virus Neuraminidase Structure and Functions
McAuley, J. L., Gilbertson, B. P., Trifkovic, S., Brown, L. E., & McKimm-Breschkin, J. L. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00039 · Cited by 466
Self-citationA brief review of influenza virus infection
Javanian, M., Barary, M., Ghebrehewet, S., Koppolu, V., Vasigala, V., & Ebrahimpour, S. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26990 · Cited by 458
Drug resistance in influenza A virus: the epidemiology and management
Hussain, M., Galvin, H., Haw, T. Y., Nutsford, A., & Husain, M. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s105473 · Cited by 439
Metadata
- Authors
- McKimm‐Breschkin, J. L.
- Venue
- Influenza and Other Respiratory Viruses
- Publisher
- Wiley
- Published
- 2012-12-28
- Volume
- 7
- Issue
- s1
- Pages
- 25-36
- ISSN
- 1750-2640 (ISSN-L)
- 1750-2659
- OpenAlex
- W1483512866
- Cited by
- 390
- References
- 75
- FWCI
- 10.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.